Hong Kong Authorities Warn Public Against Three Weight-Loss Drugs
This article was originally published in PharmAsia News
Executive Summary
Hong Kong's health department issued a warning to the healthcare community about adverse effects from drugs containing orlistat, the active pharmaceutical ingredient in three weight-loss treatments
|
Hong Kong's health department issued a warning to the healthcare community about adverse effects from drugs containing orlistat, the active pharmaceutical ingredient in three weight-loss treatments. The warning by the Department of Health of Hong Kong Special Administrative Region government was a response to U.S. FDA cautionary advisories. The drugs involved are Roche's Xenical , GlaxoSmithKline's Alli , and Zerocal . The U.S. agency said the API could lead to sever liver damage. Xenical and Zerocal require physician prescriptions in Hong Kong, Alli can be dispensed under pharmacist supervision. (Click here for more) "HK Health Authority Issues Warning On Orlistat Drugs Following FDA Advice" - Xinhua (China) (5/28/10) |